Search clinical trials for: CAR T cells

Total 24692 results

Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Everett Meyer
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative Syndrome

United States
Beijing Immunochina Medical Science & Technology...
Guangdong Provincial People's Hospital

Not yet recruiting

IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma

China
City of Hope Medical Center

Recruiting

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

HIV-1

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Gynecologic Cancer | Ovarian Cancer | Metastatic Cancer | Cervix Cancer | Advanced Cancer

China
Chongqing Precision Biotech Co., Ltd
The First Affiliated Hospital of Nanchang University

Recruiting

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Metastatic Cancer | Cervix Cancer | Advanced Cancer

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal CAR-T Cells Targeting AML

Acute Myeloid Leukemia

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

United States
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Second Affiliated Hospital of Guangzhou Medical...
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Zhaotai InVivo... and other collaborators

Recruiting

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

Hepatocellular Carcinoma | CAR | Immunotherapy | Squamous Cell Lung Cancer | GPC3 Gene Inactivation | T Cell

China
Shanghai Tongji Hospital, Tongji University School...
Shanghai AbelZeta Ltd.

Completed

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

B Cell Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Renal Cell Carcinoma | Advanced Cancer | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University

Completed

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Christian Hinrichs
National Cancer Institute (NCI)

Not yet recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical Cancer | HPV-Related Malignancy | Vulvar Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Associated Cervical Carcinoma | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
Porteus, Matthew, MD
California Institute for Regenerative Medicine (CIRM)

Recruiting

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Hematologic Diseases

United States
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Philadelphia Positive Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Adult

China
Shanghai Changzheng Hospital

Recruiting

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Chimeric Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors

United States
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Lung Cancer | Rectal Cancer | Colon Cancer | Pancreas Cancer

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer

China
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Mesothelin Positive Tumors

China
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Xuanwu Hospital, Beijing
Bioray Laboratories

Not yet recruiting

Universal CAR-T Cells in Patients With Refractory Autoimmune Diseases of the Nervous System.

Multiple Sclerosis | Neuromyelitis Optica Spectrum Disorders | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Myasthenia Gravis, Generalized

China
George Papanicolaou Hospital
General Hospital Of Thessaloniki Ippokratio

Recruiting

Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients (CoV-2-STs)

Severe COVID-19

Greece
Xijing Hospital

Unknown

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

Recurrent Glioblastoma | CD147 Positive

China

Search clinical trials for: CAR T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations